…if IPR can reduce lawsuits, then its generally good for bios.
If the USSC retains the right to initiate an IPR to challenge a US patent, it will be somewhat bearish for biotech companies in general, but bullish for FoB companies such as MNTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”